patent.fyi
Applications  /  US 2026/0354442
United States Patent Application Publication

US 2026/0354442 A1

Published
Nov 12, 2026
Filed
May 4, 2026
Earliest date on the face
May 5, 2025
Classification
A24B 15/385
First published here
Nov 18, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Lipid matrix for release

What ifWhat if solid lipid particles carried the active agent in an oral lozenge?
Claim language“a resin base component”

A spray-chilled blend of glyceryl behenate and dispersed active salt forms solid particles that are blended into the lozenge. As the lozenge dissolves, saliva enters pores in the particles and dissolves the exposed salt.

1.4Piperidine ring in the active

What ifWhat if the active agent contained a six-membered piperidine ring attached to the pyridine ring?
Claim language“a substituted 3-(1-methylpyrrolidin-2-yl)pyridine”

In 3-(1-methylpiperidin-2-yl)pyridine, the saturated ring contains five carbon atoms and one nitrogen atom. Protonation at the saturated ring nitrogen supplies the positive charge for loading onto a carboxylate resin.

1.8Hydrogen at both positions

What ifWhat if R7 and R8 were both hydrogen and R5 were methyl?
Claim language“at least one of R7 and R8 is not hydrogen”

The R5 methyl group preserves a substitution on the scaffold while both R7 and R8 carry hydrogen. The protonated amine binds to a cation-exchange resin, and dissolved ions in saliva drive release.

1.9Methylene bridge between rings

What ifWhat if a single methylene group linked the pyridine and azetidine rings?
Claim language“L is a bond or —OCH2—*”

A carbon–carbon bond joins pyridine C3 to the methylene carbon, and a second carbon–carbon bond joins that carbon to azetidine C2. The azetidine nitrogen supplies a protonation site for binding to a carboxylate resin.

1.10Hydroxyl at the R9 position

What ifWhat if R9 were a hydroxyl group attached directly to the ring?
Claim language“hydrogen, alkyl, alkoxy, halogen, and cyano”

The ring bonds directly to the oxygen of the hydroxyl group, which provides a hydrogen-bond donor for interaction with water. During resin loading, the protonated azetidine nitrogen supplies the charge for association with carboxylate sites.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Resin references for dissolution instrument checks

A pharmaceutical testing laboratory uses the active-loaded resin as a reference specimen for a flow-through dissolution instrument. A weighed portion of resin sits between two porous frits while artificial saliva flows through the cell at a fixed temperature and flow rate. Timed effluent samples provide a release curve that the laboratory compares with a reference curve for the same resin lot.

Component substitution

Carboxylated acrylic resin for active binding

A crosslinked acrylic cation-exchange resin bearing carboxyl groups serves as the resin base. The sodium-form resin contacts an aqueous solution of the active at a pH where the resin carries carboxylate groups and the active carries a positive charge. The active displaces sodium on the resin, and filtration and rinsing separate the loaded particles from dissolved material. Saliva supplies exchangeable cations that displace the bound active during use.

Parameter or scale variation

Two particle size fractions in one pouch

The same resin grade is sieved into 150–250 micrometre and 425–600 micrometre fractions before loading. Each fraction is loaded separately to the same active content per gram of dry resin, then the fractions are blended at a 30:70 dry mass ratio and sealed in a permeable oral pouch. Saliva wets both fractions through the pouch wall, and the smaller particles provide shorter diffusion paths for the dissolved active.

Combination with existing systems

Resin granules in a bilayer tablet

A bilayer rotary tablet press places a rapidly dispersing layer of loaded resin granules against an inactive, slowly eroding cellulose layer. The press lightly compacts the first fill, adds the second fill, and compresses both layers together. The loaded layer breaks up during oral use and exposes the resin particles to saliva while the cellulose layer erodes.

Porous film coating on resin granules

A fluidized-bed coater applies a film of ethylcellulose and water-soluble polyethylene glycol to the loaded resin granules. The coater dries the granules to a specified coating mass gain, and the coated granules are filled into a saliva-permeable pouch. Saliva dissolves the polyethylene glycol and opens pores through which ions enter the coating and released active diffuses out.

Automated or data-driven variant

Automated monitoring of resin loading

A stirred loading vessel holds the resin slurry and feeds a filtered liquid sample through an automated sampler to a liquid chromatograph with ultraviolet detection. Control software calculates the mass of dissolved active from the measured concentration and the current liquid volume, accounting for active removed in earlier samples. The software opens the vessel outlet to a solids filter after the calculated resin loading reaches the batch target and successive readings stabilize within a preset tolerance.

Specific version of a part

Ethyl at the R8 position

R8 is ethyl (–CH2CH3), a two-carbon alkyl group attached through its methylene carbon. R7 is hydrogen.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0325892 A1
Published
Dec 31, 2009
Filed
May 1, 2008
Class
A01N 43/40
Document BUS 2019/0263768 A1
Published
Aug 29, 2019
Filed
Oct 16, 2018
Class
C07D 307/92
Claim 1
Document A
Document B
1.1a resinate complex, the resinate complex comprising a resin base component and one or more active agents associated with the resin base component, selected from: (i) a substituted 3-(1-methylpyrrolidin-2-yl)pyridine having a structure according to Formula I: wherein R1, R2, R3, and R4 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, amino, halogen, and cyano
1.2wherein any of said alkyl, alkoxy, cycloalkyl, alkenyl, alkenyl, alkynyl, aryl, alkylaryl, and amino may optionally be substituted
Y represents 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-yl when n=0-3 and L represents a single bond, or Y represents hydrogen, C1-C4 alkyl, phenyl, 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-yl
A · US 2009/0325892 A1 · claim 1
In the aforementioned exemplary substitutents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle and aryl can themselves be optionally substituted.
B · US 2019/0263768 A1 · ¶ 115
1.3at least one of R1, R2, R3, and R4 are not hydrogen
An alternative method for the preparation of sulfides of formula (A4), wherein R1, S and L taken together form a ring, n=0, m=0, and Y=6-halo, 6-(C1-C4)alkyl, 6-(C1-C4)haloalkyl or 6-(C1-C4)alkoxy substituted 3-pyridyl is highlighted in Scheme H.
A · US 2009/0325892 A1 · ¶ 33
1.4(ii) a substituted 3-(1-methylpyrrolidin-2-yl)pyridine having a structure according to Formula II: wherein R5 and R6 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, cycloalkyl, alkenyl, alkynyl, aryl, alkylaryl, amino, halogen, and cyano
1.5wherein any of said alkyl, alkoxy, cycloalkyl, alkenyl, alkenyl, alkynyl, aryl, alkylaryl, and amino may optionally be substituted
Y represents 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-yl when n=0-3 and L represents a single bond, or Y represents hydrogen, C1-C4 alkyl, phenyl, 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-yl
A · US 2009/0325892 A1 · claim 1
In the aforementioned exemplary substitutents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle and aryl can themselves be optionally substituted.
B · US 2019/0263768 A1 · ¶ 115
1.6R7 is selected from the group consisting of hydrogen and CH3
1.7R8 is selected from the group consisting of hydrogen and C1-C3 alkyl
R8 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, aryl or substituted aryl, alkylaryl or substituted alkylaryl;
B · US 2019/0263768 A1 · ¶ 47
1.8at least one of R7 and R8 is not hydrogen
1.9(iii) a 3-(azetidin-2-yl)pyridine or 3-(azetidin-2-ylmethoxy)pyridine having a structure according to Formula III: wherein L is a bond or —OCH2—*, where the asterisk indicates an attachment point to the azetidine ring
1.10R9, R10, R11, and R12 are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, and cyano
Y represents 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-yl when n=0-3 and L represents a single bond, or Y represents hydrogen, C1-C4 alkyl, phenyl, 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-yl
A · US 2009/0325892 A1 · claim 1
1.11R13 is H or CH3
1.12R14 is H or CH3.

An empty cell means only that no passage was reproduced there.

Statements in these documents
Insects are developing resistance to pesticides in current use.
A · US 2009/0325892 A1 · ¶ 4
Therefore, a need exists for new pesticides and particularly for pesticides that have new modes of action.
A · US 2009/0325892 A1 · ¶ 4
The present invention relates to a novel class of compounds as Stat3 pathway inhibitors, cancer stem cell inhibitors as well as cancer stem cell pathway inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to synthesis and pharmaceutical compositions containing such compounds.
B · US 2019/0263768 A1 · ¶ 2
Therefore, Stat3 inhibitors may be used to prevent and treat autoimmune and inflammatory diseases as well as the other diseases listed above that are caused by inflammation.
B · US 2019/0263768 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0354442 A1, claim 1, first published 2026-11-18T23:03:08-05:00, https://patent.fyi/US20260354442/, SHA-256 52e2a5d9921f07fe3a8121ce9cf12c2a83889c4849d53527b5e811651f7b6a4b
First published
Permanent addresshttps://patent.fyi/US20260354442/
Content fingerprint (SHA-256)52e2a5d9921f07fe3a8121ce9cf12c2a83889c4849d53527b5e811651f7b6a4b
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi